Results reflect bright outlook for US biotech investment but foresee potential challenges abroad
New York, San Francisco, and Carlsbad, CA – December 7, 2018 –Biotech Showcase™, one of the largest biotech investor conferences in the world, today revealed the results of a pre-conference survey of life science executives and investors regarding the 2019 biotech landscape. Several questions asked about how biotech investment may change due to US stock market volatility, the US and China trade war, and/or the UK exit from the EU. Overall, results reflect a bright outlook for US biotech investment but signal potential challenges abroad.
Survey results are available for viewing and downloading here.
“Each year life science investors and leaders gather in January in San Francisco to set the stage for deals and investments in the coming year. The results of this survey indicate industry is primed to see continued investment in both ongoing therapeutic endeavors as well as novel innovations around the globe,” said Sara Demy, founder and CEO, Demy-Colton. “We look forward to seeing how the partnering and discussions that will take place at Biotech Showcase in 2019 will reflect and influence these trends throughout the new year.”
Key highlights from the 2019 Biotech Showcase survey include:
Life science leaders do not expect the U.S. and China trade war to have an impact on their regional strategies, but they do expect it will have long-term impact on investments coming from that region
The survey also contains predictive data around:
Run concurrently with Biotech Showcase, China Showcase and Digital Medicine & Medtech Showcase will also entice investors and entrepreneurs to convene and take a look at global biotech advancements. China Showcase provides attendees an opportunity to capitalize on cross-border investment and collaborations while learning about best practices and strategies for deal making in China, while the Digital Medicine & Medtech Showcase will feature a series of presentations and thought leaders who can speak to the evolving landscape of digital health technology.
Since 2008, Demy-Colton has been at the forefront of building networks between leaders from innovative biotech companies and industry stakeholders to examine and address biotech opportunities and challenges and deliver on the promise of transformational science.
We do this through facilitating networking and biotech community development on an international scale. Our investor conferences and CEO Summits expand communities that transcend geographical boundaries establishing ongoing, high-value relationships that contributes greatly to the evolution of the biopharmaceutical ecosystems we cultivate.
We set a unique stage where biotech leaders, investors, and stakeholders can connect to realize significant opportunities for investment, learning, and growth. Our events spur introductions and thoughtful conversations. In turn, inspiration, ideas, and opportunities for investment flow. Demy-Colton’s expanding portfolio of conferences includes:
About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.
Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Cell & Gene Connect, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 48,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Tune into EBD Group’s Partnering Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. For more information please visit www.ebdgroup.com.
# # #
CG Life for Demy-Colton
(858) 457-2436 ext. 2013